Company profile
FATE THERAPEUTICS INC
NASDAQ:FATEBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FT-516 | phase1 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06308978 | phase1 | recruiting | 2024-03-28 | 2027-09-30 | Fate Therapeutics | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease |
| NCT02354417 | phase1 | terminated | 2014-12-01 | 2016-12-01 | Fate Therapeutics | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies |
| NCT07570862 | phase2 | recruiting | 2026-07-27 | 2029-07-01 | Fate Therapeutics | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis |
| NCT02354443 | phase1 | terminated | 2015-06-01 | 2016-12-01 | Fate Therapeutics | A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders |
| NCT03319459 | phase1 | completed | 2018-01-18 | 2020-05-29 | Fate Therapeutics | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors |
FDA applications (0)
No records yet.